Business Opportunities in China: The Impact of the WTO - 2nd Edition
February 15, 2007 (Press Release) --
Business Opportunities in China: The Impact of the WTO - 2nd Edition
Key points covered in this report:
The development of the Chinese pharmaceutical industry and its current status
Changes in the industry on China's accession to the WTO
The competitiveness of the Chinese pharmaceutical industry in the international market
The R&D and business opportunities for pharmaceutical firms considering alliances in China
Significant points for consideration for companies looking to capture business opportunities in China.
Additional Information
Key points covered in this report:
The development of the Chinese pharmaceutical industry and its current status
Changes in the industry on China's accession to the WTO
The competitiveness of the Chinese pharmaceutical industry in the international market
The R&D and business opportunities for pharmaceutical firms considering alliances in China
Significant points for consideration for companies looking to capture business opportunities in China.
This report discusses the state of the Chinese pharmaceutical industry and the opportunities available to companies doing business in China, and is aimed at individuals in business development and technology transfer looking to expand into China. China is one of the largest pharmaceuticals-producing countries in the world, and as it joins the World Trade Organization (WTO), it will need to integrate more completely into the global economy. This international competition will place an intense pressure on the Chinese pharmaceutical industry, and further open the door to a lucrative market for non-Chinese companies, especially for pharmaceutical producers and manufacturers.
This second edition, updated with new figures and tables based on Chinese official statistics, provides an overview of the development of the Chinese pharmaceutical industry and its current status, and a discussion of the competitiveness of the Chinese pharmaceutical industry in the international market. The report also provides an analysis of the business opportunities for pharmaceutical firms considering alliances in China, based on this research and the commitments made by Chinese authorities at the time of accession to the WTO, and concludes by highlighting the significant points for consideration for companies looking to capture such business opportunities in China.
The appendices include two case studies that explore examples of a 'Sino-foreign equity joint venture' and a 'Wholly foreign-owned company' in China, references, a glossary of terms, the source data used in the figures, and a resources section.
Who should buy the report
This report is suitable to individuals responsible for and interested in:
Board and executive management
Business development
Licensing/partnering
Deal making
Business strategy
Companies analyzed/mentioned
Case studies:
Sino-Swed Pharmaceutical Corp. LTD (SSPC)
Pfizer (China) Pharmaceuticals Limited
China
Key points covered in this report:
The development of the Chinese pharmaceutical industry and its current status
Changes in the industry on China's accession to the WTO
The competitiveness of the Chinese pharmaceutical industry in the international market
The R&D and business opportunities for pharmaceutical firms considering alliances in China
Significant points for consideration for companies looking to capture business opportunities in China.
Additional Information
Key points covered in this report:
The development of the Chinese pharmaceutical industry and its current status
Changes in the industry on China's accession to the WTO
The competitiveness of the Chinese pharmaceutical industry in the international market
The R&D and business opportunities for pharmaceutical firms considering alliances in China
Significant points for consideration for companies looking to capture business opportunities in China.
This report discusses the state of the Chinese pharmaceutical industry and the opportunities available to companies doing business in China, and is aimed at individuals in business development and technology transfer looking to expand into China. China is one of the largest pharmaceuticals-producing countries in the world, and as it joins the World Trade Organization (WTO), it will need to integrate more completely into the global economy. This international competition will place an intense pressure on the Chinese pharmaceutical industry, and further open the door to a lucrative market for non-Chinese companies, especially for pharmaceutical producers and manufacturers.
This second edition, updated with new figures and tables based on Chinese official statistics, provides an overview of the development of the Chinese pharmaceutical industry and its current status, and a discussion of the competitiveness of the Chinese pharmaceutical industry in the international market. The report also provides an analysis of the business opportunities for pharmaceutical firms considering alliances in China, based on this research and the commitments made by Chinese authorities at the time of accession to the WTO, and concludes by highlighting the significant points for consideration for companies looking to capture such business opportunities in China.
The appendices include two case studies that explore examples of a 'Sino-foreign equity joint venture' and a 'Wholly foreign-owned company' in China, references, a glossary of terms, the source data used in the figures, and a resources section.
Who should buy the report
This report is suitable to individuals responsible for and interested in:
Board and executive management
Business development
Licensing/partnering
Deal making
Business strategy
Companies analyzed/mentioned
Case studies:
Sino-Swed Pharmaceutical Corp. LTD (SSPC)
Pfizer (China) Pharmaceuticals Limited
China
Email
Print
SPAM
